₹2,012 on Monday’s trading session after the pharma stock was added to the FTSE All-World, Large-Cap, Total-Cap, and All-Cap indices. The stock hit an all-time high at ₹2,032 per share during the intraday session at 11:45 am on November 20. FTSE, an acronym for the Financial Times Stock Exchange Group, is a British company that specializes in providing global market index offerings.
The Index is a globally diversified market-capitalization-weighted benchmark that reflects the performance of stocks across large, mid, and small-cap categories. It encompasses both developed and emerging markets, making it a suitable foundation for various investment products like funds, derivatives, and exchange-traded funds. Mankind Pharma shares opened ₹19,60.35 on Monday, against previous close at ₹19,20.10 on Friday last week.
The adjustment of the Mankind Pharma stock at FTSE will take place on December 15. Mankind Pharma's inclusion in the Large-Cap index is significant, highlighting the company's standing as a major player in the Indian pharmaceutical industry, backed by a substantial market valuation. ACC, Kotak Mahindra Bank, Canara Bank, IDBI Bank, YES Bank, Union Bank of India, Indian Hotels, Jindal Steel & Power, Shriram Finance, Trent, and Tube Investments are also part of the FTSE index, apart from Mankind Pharma.
During the second quarter, Mankind Pharma witnessed a robust performance across various segments, leading to a 21% increase in its consolidated net profit to ₹511 crore. The company's revenue from operations also experienced growth, reaching ₹2,708 crore in the current period compared to ₹2,425 crore in the corresponding period of the previous year. Milestone Alert!
Livemint tops charts as the fastest growing news